Incident users of tyrosine kinase inhibitors in patients with chronic myeloid leukemia: Analysis of anticancer treatment trajectories—A French population‐based study using the French national health data system-Reference-Cited by-同舟云学术

Incident users of tyrosine kinase inhibitors in patients with chronic myeloid leukemia: Analysis of anticancer treatment trajectories—A French population‐based study using the French national health data system

Published:2022-06-07 Issue:8 Volume:97 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Vabre Clémentine¹²^ORCID,Zelmat Yoann³,Gauthier Martin⁴⁵^ORCID,Pajiep Marie³,Conte Cécile³,Lapeyre‐Mestre Maryse²³^ORCID,Dray‐Spira Rosemary¹,Zureik Mahmoud¹,Despas Fabien²³⁶

Affiliation:

1. EPI‐PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products and the French National Health Insurance Paris France

2. Equipe PEPS, CIC 1436 – INSERM University Paul Sabatier Toulouse, Toulouse University Hospital Toulouse France

3. Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology Toulouse University Hospital, Faculty of Medicine Toulouse France

4. Department of Hematology Institut Universitaire du Cancer‐Oncopole, Toulouse University Hospital Toulouse France

5. Department of Hematology Cahors Hospital Cahors France

6. INSERM DR Midi‐Pyrénées Limousin, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC) UMR1297 Université de Toulouse III Toulouse France

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26621

Reference6 articles.

1. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

2. Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study

3. Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY

4. Patterns of Tyrosine Kinase Inhibitor Utilization in Newly Treated Patients With Chronic Myeloid Leukemia: An Exhaustive Population-Based Study in France

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events;Blood Cancer Journal;2023-08-11

2. Tyrosine kinase inhibitors dosing for chronic phase chronic myeloid leukemia : The case for starting low with dasatinib (50 mg/day) and ponatinib (15 mg/day);American Journal of Hematology;2022-09-05